In light of Gynaecological Cancer Awareness Month, ANZGOG asked three of its trial and committee leaders what inspires them and what are their hopes for future gynaecological cancer research. Professor Sandi Hayes, Associate Professor Yoland Antill, [...]
The AtTEnd clinical trial is for women with advanced stage or recurrent endometrial cancer and will assess whether the use of the immune therapy atezolizumab is of additional benefit to current, first line chemotherapy combination. [...]
The HyNOVA study has officially opened to recruitment after activating its first site, Peter MacCallum Cancer Centre and Royal Women’s Hospital. Researchers of the HyNOVA study are seeking 80 participants at five sites across [...]
iPRIME is an ovarian cancer clinical trial that tests how safe and effective the combination treatment of durvalumab and tremelimumab with standard chemotherapy can be as a treatment for newly diagnosed patients with ovarian, fallopian tube or [...]
EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical [...]
WHAM (What Happens After Menopause?) was a multicentre prospective study investigating the impact of risk reducing bilateral salpingo-oophorectomy on non-cancer outcomes in young high-risk women. The ANZGOG supported study assessed the relationship between surgical menopause and [...]
SOLACE2 is a phase II national clinical trial investigating whether immunological priming could improve the subsequent response to immunotherapy in women with the most common type of ovarian cancer (high-grade serous) at the first sign of [...]
A new journal has been published by the Journal for ImmunoTherapy of Cancer for ANZGOG's PHAEDRA study. The PHAEDRA study examined the activity of the immunotherapeutic agent durvalumab in women with advanced endometrial cancer that [...]
A significant international study in cervical cancer treatment, the ANZGOG-led OUTBACK trial will be presented at the 2021 ASCO Annual Meeting Plenary Session to reveal its highly anticipated results. OUTBACK is an academic collaboration [...]
In recent news, the American Society of Clinical Oncology (ASCO) has selected OUTBACK, an ANZGOG cervical cancer study, to be presented during the Plenary Session at their upcoming 2021 Annual Meeting. OUTBACK is an international trial [...]
Australia New Zealand Gynaecological Oncology Group www.anzgog.org.au
Level 6, Lifehouse, 119-143 Missenden Road Camperdown NSW 2050 T:+61 2 8071 4880
E: contact@anzgog.org.au © 2025 ANZGOG | Copyright | Disclaimer | ANZGOG Policies | Whistleblower
Virtually every advance in cancer survival has been made on the back of clinical trials.
As the peak, national gynaecological cancer clinical trials organisation for Australia and New Zealand, ANZGOG‘s purpose is to improve outcomes and quality of life for women with gynaecological cancer by conducting research.
We conduct and promote clinical trials and undertake multidisciplinary research into the causes, prevention and treatments of gynaecological cancers.
Research Community Volunteers will have the opportunity to contribute to ANZGOG research at every stage of the development process.
Community volunteers will lend their voices to research discussions sharing their personal perspective and representing the broader views of people with lived experience of gynaecological cancer.
Opportunities range from sharing your lived experience as a participant on a research grant working party or a Trial Management Committee, through to Research Advisor and Expert roles requiring additional levels of education and expertise in research analysis.
Gynaecological cancer research is critically needed but critically underfunded. WomenCan is the fundraising arm of ANZGOG, supporting ANZGOG by funding our programs to improve life for women with gynaecological cancer.
WomenCan’s mission is to engage the community to fund pioneering discoveries that will enable women with a gynaecological cancer to live better and live longer.
WomenCan believes the power of the collective, united in a common purpose, can make a real difference in the lives of women with gynaecological cancers.
ANZGOG’s Survivors Teaching Students (STS) Program is a ground-breaking volunteer program that brings gynaecological cancer survivors and caregivers into the classrooms of health professional students to teach them about women’s experiences with the diseases.
Survivors and caregivers are in a unique position to help students understand the ‘lived experience’ of a gynaecological cancer, including the psychosocial impact, and the importance of timely diagnosis, good health communication and compassionate care.
By joining STS and sharing your story, you will have the opportunity to impact the future care of women diagnosed with a gynaecological cancer, with participating students reporting not only increased understanding of gynaecological cancers but also a deeper understanding of the patient experience to take forward into their practice.
Since the program began at ANZGOG in 2017, our volunteers have shared their stories with more than 11,000 students across Australia and New Zealand.
